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DObjective: Primary pulmonary artery sarcoma is a severe and underdiagnosed disease, with the clinical and
surgical approach not clearly established. Only a few individual case reports or small series on this topic
have been published. The aim of the present study was to report our surgical experience in this field.
Methods: FromMarch 2004 to December 2012, 13 patients underwent surgery for pulmonary artery sarcoma at
our institution. In 7 patients, the sarcoma was unilateral (53.8%), and in 6 (46.2%), the tumor had already
extended to both lungs. The surgical strategy evolved over the years, but the 2 techniques used were always
the same: pneumonectomy in 5 patients and pulmonary endarterectomy in 8.
Results: Two patients died in-hospital, both in the pneumonectomy group. The median length of the intensive
care unit and hospital stay was 1 day (range, 1-10) and 14 days (range, 11-17) for the pneumonectomy group
and 6 days (range, 3-23) and 19 days (range, 10-32) fort the pulmonary endarterectomy group, respectively.
The median survival was 26.8 months after pneumonectomy and 6.6 months after pulmonary endarterectomy.
Conclusions: Primary pulmonary artery sarcoma has a poor prognosis. The surgical strategy at our institution
included pneumonectomy, for possible radical resection, and palliative endarterectomy, to reduce symptoms
and increase the life expectancy. The correct surgical approach must be evaluated individually, according
to the tumor presentation, the presence of pulmonary hypertension, and the patient’s clinical condition. (J Thorac
Cardiovasc Surg 2014;148:113-8)Primary pulmonary artery sarcoma (PPAS) is a very rare
tumor. Mandelstamm1 reported the first description in
1923. To our knowledge, only about 300 cases have been
published as individual case report or small series.1-13 The
tumor generates from the intimal or subintimal layer of
the pulmonary artery wall6; in some cases, it has had
histologic differentiation in various cell lines, but most
tumors have been undifferentiated.6 The disease can be
often mistaken for chronic thromboembolic pulmonary
hypertension, but a complete diagnostic workup will
provide useful information: echocardiography, computed
tomography (CT), magnetic resonance imaging, lung
perfusion-ventilation scan, and positron emission tomogra-
phy.5,11 PPAS can be treated, according to the anatomic
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The Journal of Thoracic and Caor pulmonary endarterectomy (PEA). The prognosis
reported in published studies has been very poor, with
survival of 1.5 months without surgical resection and
10 months with surgical resection.12 Generally, as reported
in 2 recent studies by Mussot and colleagues7 and
Jamieson,8 the surgical approach has rarely been curative.
The use of adjuvant chemotherapy and/or radiotherapy is
an advisable practice to improve the prognosis.
The aim of the present study was to evaluate the outcome
of patients who had undergone surgery for PPAS at our
institution and to analyze the effectiveness of the different
surgical approaches.
METHODS
Patients
FromMarch 2004 to December 2012, 13 patients underwent surgery for
PPAS at our institution. From 1994 onward, a prospective dedicated
database, approved by the institutional review board, recorded the
information of patients who had been evaluated for a possible surgical
indication in the case of obstructive pulmonary artery disease. Only 1
redo case occurred because of sarcoma recurrence in 1 patient who had
undergone left pneumonectomy 6 years previously. All patients referred
to our center for pulmonary angiosarcoma underwent surgical resection
using pneumonectomy or PEA. The 64-row high-resolution CT scan
revealed a unilateral presentation in 7 patients (53.8%) and bilateral in
6 (46.2%). The origin of the tumor was proximal (the pulmonary trunk)
in 9 patients (69%), a few millimeters distal to the pulmonary valve,
with distal extension documented in 11 patients (92%). Extravascular
invasion with pulmonary wall infiltration was described in 2 cases, and
locoregional lymph node metastasis or pulmonary metastasis was
documented in 4 patients. We did not register any case of extrapulmonary
metastasis. Chemo- and radiotherapy were given preoperatively only in therdiovascular Surgery c Volume 148, Number 1 113
Abbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
CT ¼ computed tomography
PEA ¼ pulmonary endarterectomy
PPAS ¼ primary pulmonary artery sarcoma
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Dcase of tumor recurrence. The population was divided into 2 groups
according to the surgical strategy: 8 patients underwent PEA (6 bilateral
and 2 unilateral, 1 right and 1 left) and 5 patients underwent unilateral
pneumonectomy. In 3 patients, the pneumonectomy was associated with
complete resection of the pulmonary trunk and both main pulmonary
arteries, and a tubular graft was used for reconstruction of the pulmonary
artery of the contralateral lung. The preoperative characteristics of our
population are listed in Table 1. For most patients, the first diagnosis was
chronic thromboembolic pulmonary hypertension, assessed by right heart
catheterization or echocardiography.
Surgical Techniques
Emergent surgical treatment was necessary only in 1 case because of
severe hemodynamic instability. PEA was performed in 8 patients, and
the remaining 5 patients underwent pneumonectomy. At the beginning of
our experience, the preferred approach in the case of unilateral tumor
presentation was pneumonectomy, with PEA indicated only in the case
of bilateral invasion. Subsequently, our approach has changed because
we have become convinced that the presence of pulmonary hypertension
is usually associated with bilateral extension of PPAS, even in the case
of a unilateral CT pattern. Thus, pneumonectomy is currently indicated
only in the case of unilateral presentation and the absence of pulmonary
hypertension, with a potential curative goal. PEA is indicated in the case
of bilateral invasion or when any degree of pulmonary hypertension is
present, with a palliative treatment aim.
Pulmonary Endarterectomy
PEAwas performed for PPAS (Figure 1) using a technique completely
identical to that adopted for chronic thromboembolic pulmonary
hypertension.14,15 The surgical approach is a median sternotomy, and
PEA is performed using cardiopulmonary bypass (CPB) and moderate
hypothermic ventricular fibrillation. The main pulmonary arteries are
sectioned longitudinally, and the dissection plane is accurately identified.
Our surgical technique has been the same as that reported in published
studies, with some technical changes (eg, the aorta is left unclamped to
reduce the potential risk of embolization of aortic atherosclerotic plaques
and myocardial protection relies on hypothermia, left ventricular
venting, and frequent reperfusion sections).14 The cerebral protection strat-
egy has changed over time mainly to reduce the burden of hypothermic cir-
culatory arrest. Our current strategy consists of short periods (7-10
minutes) of moderate hypothermic circulatory arrest followed by short pe-
riods (5 minutes) of reperfusion, with monitoring using cerebral near-
infrared spectroscopy to determine the length of each reperfusion period.
At the end of PEA, the left ventricular vent is clamped, and bronchoscopy
is performed to verify the absence of airway bleeding. After weaning from
CPB, the pericardium is closed to reduce the formation of adhesions and
improve postoperative right ventricular function.14
Pneumonectomy
Intrapericardial pneumonectomy has also been used for PPSA. Surgical
access is obtained with median sternotomy, and PPAS is always treated
using CPB to be as proximal as possible on the pulmonary artery and
thus achieve radical resection. After opening the pericardium, the lung
affected by the tumor is accurately dissected and removed. The resection114 The Journal of Thoracic and Cardiovascular Surgis extended as proximally as possible toward the pulmonary artery, which
is always opened and, if necessary, also resected. Reconstruction of the
pulmonary artery at the opposite side of the pneumonectomy can be
performed with implantation of a vascular prosthesis, anastomosed
between the proximal portion of the pulmonary trunk and the distal part
of the preserved pulmonary artery. Myocardial protection is obtained using
the same modalities described for PEA.
RESULTS
Intraoperative Results
In 3 patients (2 bilateral and 1 unilateral right PEA) with
severe hemodynamic instability, CPB was instituted before
the induction of general anesthesia between the femoral
artery and femoral vein, with the patient under local
anesthesia. The median duration of extracorporeal circula-
tion during PEA was 227 minutes (range, 155-410).
The median duration of extracorporeal circulation during
pneumonectomy was 220 minutes (range, 130-315).
Moderate hypothermia was adopted in the case of PEA,
with a median temperature of 25C (range, 23C-30C).
The median number of circulatory arrest sessions was
6 (range, 1-14), and the median duration of total cardio-
circulatory arrest was 41 minutes (range, 3-100).
Postoperative Course and Long-Term Follow-up
The postoperative outcomes are summarized in Table 2.
In the pneumonectomy group, the 2 hospital deaths were
related to septic shock and right heart failure, respectively.
In the PEA group, no patient died in hospital. In the
pneumonectomy group, the histologic pattern of sarcoma
was undifferentiated in 4 patients and myofibroblastic
sarcoma in 1 patient. Postoperative chemo- and/or radio-
therapy were given in 2 patients: 1 died and 1 was tumor
free during the follow-up period (the last follow-up visit
was in May 2013). In the PEA group, the histologic
pattern was undifferentiated sarcoma in 2 patients and
myofibroblastic sarcoma, leiomyosarcoma, fibrosarcoma,
osteochondrosarcoma, malignant fibrous histiocytoma,
and myxofibrosarcoma in 1 patient each. Adjuvant
chemo- and/or radiotherapy were performed in 6 cases.
Of these 6 patients, 4 died and 1 developed sarcoma
recurrence during follow-up. In both groups, some patients
did not receive adjuvant therapy because their compromised
clinical condition caused premature death.
A summary of the pre-, intra-, and postoperative
characteristic of our patients is provided in Table 3.
DISCUSSION
PPAS is a rare and misdiagnosed tumor. In 1923,
Mandelstamm1 published the first description of this
sarcoma. Subsequently, Bleisch and Kraus16 presented
some information on this topic. One recent study about
PPAS surgical treatment has been published by Mussot
and colleagues7 in 2012, with a series of 31 patients. Our
cohort of 13 patients can be considered a reasonable sizeery c July 2014
TABLE 1. Preoperative patient characteristics
Pt. no. Age Gender
WHO
class Symptoms
Symptom
duration (mo) Functional pulmonary test
Pulmonary
hypertension
(mm Hg)
Smoking
status Comorbidities
1 36 F II A, CP, C, He 7 FVC 117%, FEV1 97%,
DLCO 66%
No 0 None
2 49 M III A, C, O2tp 4.5 NA No 0 Epilepsy
3 44 M III A, C 11 FVC 85%, FEV1 83%,
DLCO 60%
43 mPAP Cath 0 AF
4 55 F III A, CP 2 FVC 75%, FEV1 78%,
DLCO 63%
35 mPAP Cath 0 None
5 42 M IV A, CP, C, He 10 FVC 76%, FEV1 78%,
DLCO 88%
No 0 None
6 55 F III A, CP 5 NA 70 sPAP Echo 1 None
7 72 F IV A, CP, C 5 NA 100 sPAP Echo 0 None
8 59 M IV A, CP, C, O2tp 6 NA No 2 CAD, SH, D
9 45 F IV A, O2tp 9 NA 85 sPAP Echo 0 None
10 65 F III/IV A, CP, C 2 FVC, 87% FEV1, 85%,
DLCO NA
32 mPAP Cath 0 CAD, SH, D, COPD
11 31 M III/IV A, CP 1 NA 65 sPAP Echo 0 None
12 73 F II A, CP 11 FVC 64%, FEV1 73%,
DLCO 36%
No 0 Chronic anemia
13 77 M III/IV A, CP, C, He, O2tp 7 FVC 102%, FEV1 96%,
DLCO NA
27 mPAP Cath 0 SH, Paget disease
Patient numbers correspond to those numbers in Table 3. Pt. no., Patient number; WHO, World Health Organization; F, female; A, asthenia; CP, chest pain; C, cough;
He, hemoptysis; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; DLCO, carbon monoxide diffusion capacity; 0, no smoking;M, male; O2tp, oxygen therapy;
NA, not available; mPAP, mean pulmonary artery pressure; Cath, right heart catheterization; AF, atrial fibrillation; sPAP, systolic pulmonary artery pressure; Echo, echocardio-
graphy; 1, active smoker; 2, ex-smoker; CAD, coronary artery disease; SH, systemic hypertension; D, dyslipidemia; COPD, chronic obstructive pulmonary disease.
TABLE 2. Postoperative outcome
Unilateral
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Dseries, considering the rarity of the disease. From our
experience, the median interval from the beginning of
symptoms to the diagnosis and surgery was 6 months
(range, 1-11), comparable to the results reported in previous
studies (range, 3-12 months).5,7,17,18 This finding again
highlights the difficulty in the diagnosis and, thus, the
delay in medical treatment.5,7,17-20 In particular, the
clinical presentation usually reproduces the signs and
symptoms of chronic thromboembolic pulmonary
hypertension.7 However, some specific characteristics canFIGURE 1. Primary pulmonary artery sarcoma specimen removed using
bilateral pulmonary endarterectomy.
The Journal of Thoracic and Calead to the correct diagnosis, including the absence of
clinical status improvement or mass size reduction
after anticoagulant therapy, the unilateral lack of blood
pulmonary artery flow (unilateral pulmonary invasion),
the absence of thrombophilic risk factors, paraneoplastic
systemic symptoms, and the bulky central angiographic
presentation.8,17,18,21,22 The clinical symptoms of ourVariable PEA (n ¼8)
pneumonectomy
(n ¼ 5)
MV duration (d) 4 (1-15) 1 (1-9)
ICU stay (d) 6 (3-23) 1 (1-10)
Total postoperative hospital stay (d) 19 (10-32) 14 (11-17)
Complications (n)
Atrial fibrillation 3 (38) 1 (20)
Right heart failure 1 (13) 1 (20)
Transient neurologic event 2 (25) 0
Infection 1 (13) 1 (20)
Reoperation for bleeding 0 1 (20)
Red blood cell transfusion 0 1 (20)
Hospital mortality 0 2 (40)
Survival (mo) 6.6 26.8
Cumulative 12-mo survival
(95% CI)
37% (0.09-0.67) 67% (0.05-0.94)
Data presented as median (range) or n (%). PEA, Pulmonary endarterectomy;
MV, mechanical ventilation; ICU, intensive care unit; CI, confidence interval.
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TABLE 3. Summary of patient data
Procedure Pt. no.
Characteristic
Surgical technique Survival (mo)
CT localization
before surgery
Pulmonary
hypertension
(first diagnosis) Histologic type after surgery
Unilateral
pneumonectomy
1 Unilateral 0 IS, myofibroblastic differentiation L Pneum Alive (110)
2 Unilateral 0 Angiosarcoma slightly
differentiated, infiltrating (B)
L Pneum Dead (11)
3 Unilateral; infiltrating
arterial wall
1 (cath) IS, pleomorphic pattern
infiltrating (AþB)
R Pneum Hospital death
4 Unilateral; infiltrating
arterial wall
1 (cath) IS, high degree, infiltrating
(AþB)
L Pneum Hospital death
5 Unilateral 0 Mesenchymal high-degree
sarcoma, infiltrating (AþB)
R Pneum Dead (27)
PEA 6 Bilateral; extra-v (met) 1 (echo) IS, high degree Bilateral PEA Dead (2)
7 Bilateral; extra-v (met) 1 (echo) High-degree sarcoma; myxoid
stroma; myofibroblastic
differentiation
Bilateral PEA (CPB awake) Dead (5)
8 Unilateral 0 High-degree leiomyosarcoma
(cancer recurrence)
R-PEA (CPB awake) Dead (7)
9 Bilateral 1 (echo) Fibrosarcoma Bilateral PEA Dead (26)
10 Bilateral 1 (cath) IS, areas of osteochondrosarcoma Bilateral PEA Alive (19)
11 Bilateral; extra-v (met) 1 (echo) IS Bilateral PEA (CPB awake) Dead (8)
12 Unilateral 0 Malignant fibrous histiocytoma L PEA Alive (7)
13 Bilateral; extra-v (met) 1 (cath) Myxofibrosarcoma Bilateral PEA Dead (5)
Patient numbers correspond to those in Table 1. Pt. no., Patient number; CT, computed tomography; Unilateral, unilateral localization; 0, normal pulmonary pressure;
IS, intimal sarcoma; L, left; Pneum, pneumonectomy; B, extra-arterial wall infiltration; 1, pulmonary hypertension; cath, diagnosis of pulmonary hypertension using right heart
catheterization; A, infiltrating only arterial wall; R, right; PEA, pulmonary endarterectomy; extra-v, extravascular localization; met, metastasis; Bilateral, bilateral localization;
echo, diagnosis of pulmonary hypertension using echocardiography; CPB, cardiopulmonary bypass.
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studies and included dyspnea, asthenia, chest pain, cough,
and hemoptysis.6,12 The main signs of PPAS were jugular
venous distension, bruit over the pulmonary artery,
systolic flow murmur, hepatomegaly, edema, cyanosis,
and digital clubbing.12,21 Concerning the instrumental
diagnosis of PPAS, our most meaningful study was CT.
CT showed the tumor mass presence and the anatomic
disposition, with unilateral presentation in 7 patients
(53.8%) and bilateral extension in 6 patients (46.2%).
Moreover, the tumor mass can be better defined with
contrast-enhanced CT, which was routinely performed
in our patients.6,22,23 Similarly, magnetic resonance
imaging will be able to identify PPAS after contrast
administration; however, in our series, magnetic
resonance imaging was not adopted because the
disease was mainly defined using CT in association
with transthoracic echocardiography and right heart
catheterization. Echocardiography did not detect the
sarcoma in any of the patients in our series but
demonstrated pulmonary hypertension in 4 patients.
For the other 4 patients in our population, pulmonary
hypertension was discovered using right heart
catheterization. The importance of assessing the
pulmonary pressure is closely linked to the surgical116 The Journal of Thoracic and Cardiovascular Surgstrategy. To complete the diagnostic investigation,
positron emission tomography and ventilation-perfusion
scintigraphy scan have also been adopted in some cases to
detect the neoplastic nature of the mass and show the
pathologic ventilation ratio.7,22,23 For 2 of our patients, an
intravascular tumor biopsy was performed before surgery
to obtain the histologic diagnosis. Regarding the
histologic pattern, undifferentiated sarcoma was the most
frequent in our series and was usually a very aggressive
tumor. However, because of the small number of patients,
a correlation between the histologic pattern and prognosis
could not be determined, neither in our nor in other
studies. Some investigators5,6,24 have presented a trend
toward better survival for the myofibroblastic sarcoma,
which was also reported by Mussot and colleagues.7 In
general, regardless of the histologic type, the mean reported
survival of PPAS without surgery has been about 1.5
months; with surgery, it has been 10 to 18 months.5,12,17
From our experience, 2 patients died in-hospital after
pneumonectomy, performed at the beginning of our
experience with PPAS. Both patients had had a unilateral
CT presentation with pulmonary hypertension, a pattern
currently treated with PEA. After this change in surgical
strategy, no additional patients died in hospital. The median
survival after pneumonectomy was 26.8 months and wasery c July 2014
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survival of 67% (95% confidence interval, 0.05-0.94) and
37% (95% confidence interval, 0.09-0.67), respectively.
Considering the surgical approach, the most appropriate
strategy has been debated in published studies. Mussot
and colleagues7 reported that pneumonectomy through a
thoracotomy was at first considered the reference standard.
However, subsequently, considering the intimal onset of the
sarcoma, with a proximal presentation and centrifugal
extension, they reported that radical resection can only
be obtained with pneumonectomy performed through
sternotomy and using CPB.7 However, to preserve the
pulmonary vascular bed and delay pulmonary hypertension,
Mussot and colleagues7 began to consider PEA as the
treatment of choice. PEA can provide excellent palliative
therapy and could allow complete tumor removal.7
However, as noted by Jamieson,8 surgery has rarely been
curative for PPAS and usually has had a palliative aim.
This is because, if pulmonary hypertension is present, the
tumor will always be bilateral, or, in the absence of
pulmonary hypertension, bilateral diffusion has probably
already occurred by the time the patient presents.8 At our
center, the surgical strategy for the treatment of PPAS has
been modified over time and we have reported what we
have learned from this initial experience in the treatment
of patients and the selection of the most appropriate surgical
choice. Initially, at the beginning of our experience with
PPAS, the preferred surgical approach in the case of a
unilateral presentation was unilateral pneumonectomy to
achieve oncologic radicality. Currently, our approach has
been to use pneumonectomy only in the case of a
unilateral presentation and in the absence of pulmonary
hypertension, with a potential curative goal. This choice
has been supported by our belief that the presence
of pulmonary hypertension is associated with bilateral
PPAS extension, even in the case of a unilateral CT pattern.
As recently reported by Jamieson,8 pneumonectomy
cannot be the right choice in the presence of bilateral
involvement. Thus, PEA is now indicated in the case of
bilateral invasion or when any degree of pulmonary
hypertension is present, with a palliative aim. In addition
to these general criteria of surgical procedure selection, it
is necessary to consider other specific clinical aspects that
cannot be standardized but that might provide a guide
toward the most appropriate choice. For example, 1 patient
in our series underwent PEA, although the presentation
on CT was unilateral without pulmonary hypertension.
This strategy was adopted because of advanced age of the
patient and the high risk of postoperative bleeding with
the presence of extensive vascular adhesions in the case
of pneumonectomy. Moreover, during surgery, the tumor
was found to be easily removable with PEA. Another
patient underwent unilateral PEA despite the absence
of pulmonary hypertension because he had previouslyThe Journal of Thoracic and Caundergone pneumonectomy and had presented with tumor
recurrence.
Concerning the prognosis, depending on local recurrence
and pulmonary metastasis, Mussot and colleagues7
suggested that the adjuvant chemo- or radiotherapy should
be considered on an individualized basis. In contrast,
Jamieson8 has asserted that adjuvant therapy can be adopted
in nearly every case to extend palliation. In our series,
adjuvant therapy, chemo- and/or radiotherapy, was adopted
in 8 patients, according to the preference of the oncologist.
The other 5 patients did not receive adjuvant therapy
because their compromised clinical condition could have
caused premature death.CONCLUSIONS
Considering the rarity of the disease and the consequent
small number of patients, it was impossible to demonstrate
which treatment should be considered the reference
standard. Regardless, the prognosis of PPAS after surgical
resection remains poor. Our results showed a trend toward
better survival after pneumonectomy; however, given the
small number of cases, it was not possible to make reliable
conclusions. In our practice, the correct surgical approach
has been evaluated individually, according to the tumor
presentation, the presence of pulmonary hypertension, and
the patient’s clinical conditions.References
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